U.K. Parliament to debate NHS access for Vertex's Orkambi

The U.K. Parliament's House of Commons will debate on March 19 a petition to make cystic fibrosis drug Orkambi ivacaftor/lumacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) available on the NHS. The U.K.'s NICE recommended against approval of

Read the full 364 word article

User Sign In